CoChat

A narrative review of lifestyle management guidelines for metabolic dysfunction–associated steatotic liver disease

Open access

The DOI matches its Crossref record; 164 of the 164 references it cites were found in a registry or an index.

Abstract

Background and Aims: Metabolic dysfunction–associated steatotic liver disease management guidelines have been published worldwide; we aimed to summarize, categorize, and compare their lifestyle intervention recommendations. Approach and Results: We searched metabolic dysfunction–associated steatotic liver disease/NAFLD management guidelines published between January 1, 2013, and June 31, 2024, through databases including PubMed/MEDLINE, Cochrane, and CINAHL. In total, 35 qualifying guidelines were included in the final analysis. Guideline recommendations were categorized into 5 domains (ie, weight reduction goals, physical activity, nutrition, alcohol, and tobacco smoking) and were ranked based on how frequently they appeared. A recommendation was defined as widely adopted if recommended in ≥24 (≥66.6%) of the guidelines. These included increasing physical activity; reducing body weight by 7%–10% to improve steatohepatitis and/or fibrosis; restricting caloric intake; undertaking 150–300 or 75–150 minutes/week of moderate or vigorous-intensity physical activity, respectively; and decreasing consumption of commercially produced fructose. The least mentioned topics, in ≤9 of the guidelines, evaluated environmental determinants of health, mental health, referring patients for psychological or cognitive behavioral therapy, using digital health interventions, and assessing patients’ social determinants of health. Conclusions: Most guidelines recommend weight reduction through physical activity and improving nutrition, as these have proven positive effects on health outcomes when sustained. However, gaps regarding mental health and the social and environmental determinants of metabolic dysfunction–associated steatotic liver disease were found. To optimize behavioral modifications and treatment, we recommend carrying out studies that will provide further evidence on social support, environmental factors, and mental health, as well as further exploring digital health interventions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/hep.0000000000001058

Cites

164 of 164 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical abstract
Graphical abstract CC BY-NC-ND · PubMed Central
FIGURE 1 Summary of recommendations and mentions of lifestyle interventions for patients living with metabolic dysfunction–associated steatotic liver disease and overweight or obesity. The recommendations were categorized by the number of times that they appeared in international, national, and local guidelines. The recommendation frequency categories were: widely adopted: if recommended in ≥24 (>66.7%) guidelines; occasionally adopted: if recommended in 12–23 (33.3%–66.7%) guidelines; and inconsistently adopted: if recommended in <12 (<33.3%) guidelines. The number listed at the end of each statement represents how many guidelines mentioned or recommended it. *Represents opposite recommendations under the topic of weight reduction targets to improve liver steatosis; #Represents opposite recommendations under the topic of alcohol consumption. Abbreviation: MASLD, metabolic dysfunction–associated steatotic liver disease.
FIGURE 1 Summary of recommendations and mentions of lifestyle interventions for patients living with metabolic dysfunction–associated steatotic liver disease and overweight or obesity. The recommendations were categorized by the number of times that they appeared in international, national, and local guidelines. The recommendation frequency categories were: widely adopted: if recommended in ≥24 (>66.7%) guidelines; occasionally adopted: if recommended in 12–23 (33.3%–66.7%) guidelines; and inconsistently adopted: if recommended in <12 (<33.3%) guidelines. The number listed at the end of each statement represents how many guidelines mentioned or recommended it. *Represents opposite recommendations under the topic of weight reduction targets to improve liver steatosis; #Represents opposite recommendations under the topic of alcohol consumption. Abbreviation: MASLD, metabolic dysfunction–associated steatotic liver disease.CC BY-NC-ND · PubMed Central
FIGURE 2 Subsynthesis of lifestyle recommendations found in metabolic dysfunction–associated steatotic liver disease clinical practice guidelines. Category definitions: (1) Omitted recommendation: the recommendation or topic was not included; (2) mention without recommendation: the topic was discussed generally, but no specific recommendation was provided; (3) recommendation in supportive text or table without quality or grading indication: the recommendation was found within the text or display items, but there was no indication of its quality or grading; and (4) explicit recommendation with quality and grading evaluation: the recommendation was explicitly highlighted and included and evaluation of its quality (ie, A: high, B: medium, or C: low) and grading (ie, 1: strong or 2: weak), according to the GRADE system. Abbreviations: APASL, Asian Pacific Association for the Study of the Liver; GRADE, Grading of Recommendations Assessment, Development, and Evaluation; m, minutes; w, week.
FIGURE 2 Subsynthesis of lifestyle recommendations found in metabolic dysfunction–associated steatotic liver disease clinical practice guidelines. Category definitions: (1) Omitted recommendation: the recommendation or topic was not included; (2) mention without recommendation: the topic was discussed generally, but no specific recommendation was provided; (3) recommendation in supportive text or table without quality or grading indication: the recommendation was found within the text or display items, but there was no indication of its quality or grading; and (4) explicit recommendation with quality and grading evaluation: the recommendation was explicitly highlighted and included and evaluation of its quality (ie, A: high, B: medium, or C: low) and grading (ie, 1: strong or 2: weak), according to the GRADE system. Abbreviations: APASL, Asian Pacific Association for the Study of the Liver; GRADE, Grading of Recommendations Assessment, Development, and Evaluation; m, minutes; w, week.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 164 references

Research works printed but not linked: 1

  1. Fassio, 2020, Guía de diagnóstico y tratamiento del hígado graso no alcohólico. Asociación argentina para el estudio de las enfermedades del hígado, año 2019, Medicina, 80, 371

Cited by

See all 33

Metadata

Authors
Ivancovsky Wajcman, D., Byrne, C. J., Dillon, J. F., Brennan, P. N., Villota-Rivas, M., Younossi, Z. M., Allen, A. M., Crespo, J., Gerber, L. H., & Lazarus, J. V.
Affiliations
  • Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain
  • University of Dundee (GB)
  • Inova Health System (US)
  • Mayo Clinic (US)
  • Marqués de Valdecilla University Hospital (ES)
  • City University of New York (US)
Corresponding author
Lazarus, Jeffrey V.
Venue
Hepatology
Published
2024-08-15
Volume
83
Issue
5
Pages
1303-1325
ISSN
  • 0270-9139 (ISSN-L)
  • 1527-3350
OpenAlex
W4401793309
Cited by
33
References
164
Citations by year
2026: 16 · 2025: 16 · 2024: 1
FWCI
2.16
Type
journal article
Language
en
Open access
Locations
  • Hepatology (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • Discovery Research Portal (University of Dundee) (submittedVersion, cc-by-nc-nd)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
non-alcoholic fatty liver disease, lifestyle intervention, weight loss, physical activity, nutrition, alcohol consumption, smoking, fructose consumption, social determinants of health, mental health, digital health interventions, behavior change
MeSH terms
Humans, Life Style, Exercise, Practice Guidelines as Topic, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A narrative review of lifestyle management guidelines for metabolic dysfunction–associated steatotic liver disease. https://app.cochat.ai/papers/10.1097/hep.0000000000001058
The paper
Ivancovsky Wajcman, D., Byrne, C. J., Dillon, J. F., Brennan, P. N., Villota-Rivas, M., Younossi, Z. M., Allen, A. M., Crespo, J., Gerber, L. H., & Lazarus, J. V. (2026). A narrative review of lifestyle management guidelines for metabolic dysfunction–associated steatotic liver disease. Hepatology. https://doi.org/10.1097/hep.0000000000001058

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.